Inventor · disambiguated record
Peng Chen
Also filed as: CHEN PENG · CHEN PENG-JEN
5 granted patents·20 pending applications·1 citations·filing 2007–2025
61Inventor score
Files withANTENGENE BIOLOGICS LTD6WATERS TECHNOLOGIES CORP3ANTENGENE DISCOVERY LTD2SUNSHINE LAKE PHARMA CO LTD2UNIV CALIFORNIA2
Top patents by PatentIndex Score
25 records- 0171US8202553B2Methods and compositions for treating blood circulation disordersLAN GUIHUA·Filed 2009·Granted Jun 19, 2012·1 cites·6 claims
- 0267US2024092959A1Bonded hybrid polymer non-porous particles and their use for bioseparationsWATERS TECHNOLOGIES CORP·Filed 2023·Application pending·0 cites
- 0365US2024122879A1Compositions and methods for treating ocular chemical burnsOHIO STATE INNOVATION FOUNDATION·Filed 2023·Application pending·0 cites
- 0458US2025361295A1Novel anti-lilrb4 antibodies and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 0558US2023126856A1Reagents for rapid chiral labeling and analysis of amine containing enantiomersWATERS TECHNOLOGIES CORP·Filed 2022·Application pending·0 cites
- 0655US12371509B2Antibodies specific to MUC18MULTITUDE INC·Filed 2021·Granted Jul 29, 2025·0 cites·18 claims
- 0754US10114024B2Biomolecule-graphene quantum dot conjugates and use thereofUNIV NANYANG TECH·Filed 2014·Granted Oct 30, 2018·0 cites·11 claims
- 0854US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 0953US2024400689A1Novel anti-cd276 antibodies and the uses thereofANTENGENE BIOLOGICS LTD·Filed 2022·Application pending·0 cites
- 1053US2025368734A1Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1152US2024052052A1Novel anti-cd24 antibodiesANTENGENE BIOLOGICS LTD·Filed 2022·Application pending·0 cites
- 1252US2022062401A1Vaccine compositions for clostridium difficileUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 1352US2025223358A1Novel anti-cd3 antibodies and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1451US2025270538A1Methods for the separation of nucleic acids with slalom chromatographyWATERS TECHNOLOGIES CORP·Filed 2025·Application pending·0 cites
- 1551US2023339977A1Substituted heteroaryl compound, and composition and application thereofSUNSHINE LAKE PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1651US2024174649A1Cullin-ring e3 ubiquitin ligase 4 inhibitor compounds and methods of their useICAHN SCHOOL MED MOUNT SINAI·Filed 2022·Application pending·0 cites
- 1750US2023095569A1Antibodies and methods for treating claudin-associated diseasesANTENGENE BIOLOGICS LTD·Filed 2021·Application pending·0 cites
- 1849US12252515B2Compositions and methods for inhibiting Wnt signalingCHILDRENS MEDICAL CENTER·Filed 2019·Granted Mar 18, 2025·0 cites·9 claims
- 1949US2023212170A1Inhibitors of kras g12c protein and uses thereofSHANGHAI ANTENGENE CORPORATION LTD·Filed 2021·Application pending·0 cites
- 2048US2022340944A1Allulose 3-epimerase mutant, engineered bacterium expressing same, and immobilized enzyme and immobilization method thereofTIANJIN INST IND BIOTECHNOLOGY CAS·Filed 2020·Application pending·0 cites
- 2147US2024033354A1A broadly neutralizing molecule against clostridium difficile toxin bUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2246US2007248581A1Mgra is a redox regulator of antibiotic sensitivity and virulenceUNIV CHICAGO·Filed 2007·Application pending·0 cites
- 2346US2023295166A1Atr inhibitors and uses thereofANTENGENE DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 2445US2023339927A1Atr inhibitors and uses thereofANTENGENE DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 2537US10683297B2Substituted heteroaryl compounds and methods of useSUNSHINE LAKE PHARMA CO LTD·Filed 2018·Granted Jun 16, 2020·0 cites·25 claims
Join the waitlist — get patent alerts
Get an alert when Peng Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →